For years, $7.2B in U.S. government-backed neuroperformance research sat untouched—proven cognitive enhancements with no commercial application.David Bach saw the gap. Optios is bridging classified IP with market demand, transforming military-grade neuroscience into real-world performance gains.The upside? Monumental. The imbalance? Even bigger.We dive into:• how declassified DOD research is unlocking a new frontier in neurotech• the hidden psychology behind winning investor buy-in• what $600M+ in exits taught him about product-market fitConnect with us here:1. David Bach:https://www.linkedin.com/in/david-bach-md-0b81b29/2. George Bandarian:https://www.linkedin.com/in/georgebandarian/3. Untapped Ventures:https://www.linkedin.com/company/untappedventures00:00 Trailer01:20 Introduction01:46 David Bach04:46 Journey to Harvard10:26 Founding Optios16:08 Tech Transfer and Market Research22:09 The Future of Neuro-Performance28:33 Key Lessons for Founders33:34 Fundraising Insights37:29 Closing Thoughts

Ver todos los episodios